Literature DB >> 801791

T and B cells in myelomatosis.

S V Jones, H McFarlane.   

Abstract

The majority of treated patients with myelomatosis had a significantly decreased number of T cells as measured by both lymphocyte stimulation to phytohaemagglutinin (PHA) and by their ability to form spontaneous rosettes with sheep red blood cells (SRBC). Seven untreated patients also had markedly depressed T cells. On the other hand, B-cell numbers' were significantly increased in the majority of the patients as judged by increased lymphocyte stimulation to pokeweed mitogen (PWM) and the markedly increased numbers of rosettes that were formed with antibody-coated complement activated SRBC, as well as by immunofluorescence cell markers to monospecific immunoglobulin antiserum.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 801791     DOI: 10.1111/j.1365-2141.1975.tb00889.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Lymphocyte subsets in the peripheral blood of patients with multiple myeloma and benign monoclonal gammopathy.

Authors:  F Herrmann; A Lochner; B Jauer; G Sieber; H Rühl
Journal:  Klin Wochenschr       Date:  1983-08-15

2.  The development and nature of immune deficit in primates in response to malnutrition.

Authors:  S T Qazzaz; J H Mamattah; T Ashcroft; H McFarlane
Journal:  Br J Exp Pathol       Date:  1981-10

3.  Defective monocyte chemotactic responsiveness in patients with multiple myeloma and benign monoclonal gammapathy.

Authors:  F Dammacco; A Miglietta; M T Ventura; L Bonomo
Journal:  Clin Exp Immunol       Date:  1982-02       Impact factor: 4.330

4.  Enzyme-induced modification of the surface properties of lymphoid cells in malignant disease. I. Effect of trypsin on rosette formation by lymphocytes in myelomatosis.

Authors:  J O Fajumi
Journal:  Br J Cancer       Date:  1980-02       Impact factor: 7.640

5.  Lymphocyte defect in plasmacytoma-bearing mice.

Authors:  I Brus; J Brent; V P Hollander
Journal:  Br J Cancer       Date:  1978-04       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.